Literature DB >> 20664627

Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.

Pantelis A Sarafidis, Anastasios N Lasaridis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20664627     DOI： 10.1038/nrneph.2010.86

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Guidelines for the diagnosis and treatment of pulmonary hypertension.

Authors:  N Galiè; M M Hoeper; M Humbert; A Torbicki; J-L Vachiery; J A Barbera; M Beghetti; P Corris; S Gaine; J S Gibbs; M A Gomez-Sanchez; G Jondeau; W Klepetko; C Opitz; A Peacock; L Rubin; M Zellweger; G Simonneau
Journal:  Eur Respir J       Date:  2009-09-12       Impact factor: 16.671

Review 2.  Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications.

Authors:  Pantelis A Sarafidis; Luis M Ruilope
Journal:  Am J Nephrol       Date:  2006-05-29       Impact factor: 3.754

3.  Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.

Authors:  Jennifer M Sasser; Jennifer C Sullivan; Janet L Hobbs; Tatsuo Yamamoto; David M Pollock; Pamela K Carmines; Jennifer S Pollock
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

4.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

Authors:  René R Wenzel; Thomas Littke; Susan Kuranoff; Christiane Jürgens; Heike Bruck; Eberhard Ritz; Thomas Philipp; Anna Mitchell
Journal:  J Am Soc Nephrol       Date:  2009-01-14       Impact factor: 10.121

Review 5.  Insulin resistance and endothelin: another pathway for renal injury in patients with the cardiometabolic syndrome?

Authors:  Pantelis A Sarafidis; Anastasios N Lasaridis
Journal:  J Cardiometab Syndr       Date:  2008

Review 6.  The endothelin system and its antagonism in chronic kidney disease.

Authors:  Neeraj Dhaun; Jane Goddard; David J Webb
Journal:  J Am Soc Nephrol       Date:  2006-03-15       Impact factor: 10.121

Review 7.  Physiology and pathology of endothelin-1 in renal mesangium.

Authors:  Andrey Sorokin; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2003-10

Review 8.  Endothelin as a clinical target in the treatment of systemic hypertension.

Authors:  Vinoy S Prasad; Chandrasekar Palaniswamy; William H Frishman
Journal:  Cardiol Rev       Date:  2009 Jul-Aug       Impact factor: 2.644

9.  Avosentan for overt diabetic nephropathy.

Authors:  Johannes F E Mann; Damian Green; Kenneth Jamerson; Luis M Ruilope; Susan J Kuranoff; Thomas Littke; Giancarlo Viberti
Journal:  J Am Soc Nephrol       Date:  2010-02-18       Impact factor: 10.121
  9 in total
  4 in total

Review 1.  Species differences in regulation of renal proximal tubule transport by certain molecules.

Authors:  George Seki; Motonobu Nakamura; Masashi Suzuki; Nobuhiko Satoh; Shoko Horita
Journal:  World J Nephrol       Date:  2015-05-06

2.  Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis.

Authors:  Olivia Lenoir; Marine Milon; Anne Virsolvy; Carole Hénique; Alain Schmitt; Jean-Marc Massé; Yuri Kotelevtsev; Masashi Yanagisawa; David J Webb; Sylvain Richard; Pierre-Louis Tharaux
Journal:  J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 10.121

3.  Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis.

Authors:  Olivia Lenoir; Magali Jasiek; Carole Hénique; Léa Guyonnet; Björn Hartleben; Tillmann Bork; Anna Chipont; Kathleen Flosseau; Imane Bensaada; Alain Schmitt; Jean-Marc Massé; Michèle Souyri; Tobias B Huber; Pierre-Louis Tharaux
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

4.  Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy.

Authors:  Roderick J Tan; Lili Zhou; Dong Zhou; Lin Lin; Youhua Liu
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.